ArticleJournal of neuro-oncology2026
Optimizing the Stupp protocol for treatment of glioblastoma: eliminating age bias, enhancing treatment timing, use of stereotactically-guided sequential boost, and dexamethasone dosing.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Completion of ≥6 cycles of adjuvant temozolomide is the strongest modifiable prognostic factor in glioblastoma: a 17-year real-world cohort of 319 glioma patients from a single Chinese center.Frontiers in oncology · 2026Article
- Tumor treating fields plus temozolomide maintenance after radiochemotherapy in Chinese grade 4 gliomas: Efficacy and predictive biomarkers.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Stupp protocol is the standard of care for glioblastoma, yet implementation remains inconsistent, particularly regarding age selection, treatment timing, dexamethasone dosing, and usage of stereotactically-guided sequential boost (SGS-Boost). This study evaluated how treatment intervals, dexamethasone exposure, and sequential fractionated radiotherapy boost affect survival, with emphasis on eliminating age bias.
methodsWe retrospectively analyzed 269 patients meeting the 2021 World Health Organization criteria for glioblastoma treated at our institution. Of these, 173 patients underwent maximal safe resection followed by chemoradiotherapy, and adjuvant temozolomide was planned. Following stratification by O
resultsStupp protocol completion significantly improved OS in both methylated and unmethylated populations (p < 0.0001). In methylated patients, both initiating chemoradiotherapy 32-49-days post-surgery and adding SGS-Boost independently improves outcome (p < 0.0001). Poor outcomes were found when dexamethasone was given at ≥ 1.2 mg/m
conclusionsOptimizing treatment intervals including timing of onset of chemoradiation, incorporating a SGS-Boost in methylated patients, minimizing dexamethasone, and eliminating age bias significantly improves survival. Refinements of the Stupp protocol maximize therapeutic benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.